Replimune to resubmit melanoma drug after FDA’s Makary leaves

By FinMar NewsMay 29, 2026

Thomas Fuller | Lightrocket | Getty ImagesReplimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at…

Replimune to resubmit melanoma drug after FDA’s Makary leaves

Energy News

WIEN Academy positions women for opportunities in energy sector –

Oil price, WTI, Brent: U.S.-Iran fighting pause holds

As clean energy investment faces headwinds, superannuation could help fill

Russian attack cuts power to around 150,000 in Chernihiv

Banks News

Banking Industry Trade Associations File Comprehensive Amicus Brief

SEC Issues Relief for ETFs Exceeding Industry Concentration Caps

Capgemini: Why AI is Redefining the Future of Banking

ServiceNow backs BUSINESSNEXT with USD 40 million to advance AI-led banking

Real Estate News

Exclusive | A London Penthouse in Belgravia Backed by Qatar Lists for $64

Goddard approves tax breaks for 72-unit apartment expansion at Genesis

Project Snapshot: Mixed-use building rising on former Westover Place

Kendra Wilkinson breaks down in tears after real estate career setback